OUR PRODUCTS
United States
TARPEYO has received full approval by the United States (US) Food and Drug Administration (FDA) for use in the US.
It is marketed in the US exclusively by Calliditas Therapeutics AB.
Europe
Kinpeygo® has been granted full marketing authorization by the European Commission (EC). It is marketed in the European Economic Area (EEA), United Kingdom and Switzerland exclusively by STADA Arzneimittel AG.